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Urinary neutrophil gelatinase-associated lipocalin (Ngal or
lipocalin 2) is a very early and sensitive biomarker of kidney
injury. Here we determined the origin and time course of
Ngal appearance in several experimental and clinically
relevant renal diseases. Urinary Ngal levels were found to be
markedly increased in lipoatrophic- and streptozotocin-
induced mouse models of diabetic nephropathy. In the latter
mice, the angiotensin receptor blocker candesartan
dramatically decreased urinary Ngal excretion. The
reabsorption of Ngal by the proximal tubule was severely
reduced in streptozotocin-induced diabetic mice, but
upregulation of its mRNA and protein in the kidney was
negligible, compared to those of control mice, suggesting
that increased urinary Ngal was mainly due to impaired renal
reabsorption. In the mouse model of unilateral ureteral
obstruction, Ngal protein synthesis was dramatically
increased in the dilated thick ascending limb of Henle and N
was found in the urine present in the swollen pelvis of the
ligated kidney. Five patients with nephrotic syndrome or
interstitial nephritis had markedly elevated urinary Ngal
levels at presentation, but these decreased in response to
treatment. Our study shows that the urinary Ngal level may
be useful for monitoring the status and treatment of diverse
renal diseases reflecting defects in glomerular filtration
barrier, proximal tubule reabsorption, and distal nephrons.
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Neutrophil gelatinase-associated lipocalin (Ngal) is a differ-
entiation inducer for epithelia in embryonic kidney, whose
expression is dramatically increased in acute kidney injury
(AKI).1–5 Ngal exerts a spectrum of iron-dependent biological
activities,1–4,6 and administration of Ngal protein mitigates
renal injury in mice, suggesting that functional consequence
of Ngal upregulation is renoprotection.2 Ngal mRNA levels in
the kidney are increased as much as by 1000-fold during renal
ischemia–reperfusion injury in mice.2,7 Ngal protein starts to
accumulate within a few hours in the blood and urine during
AKI.8–11 These characteristics of Ngal have made it a
promising biomarker of AKI that is found in the blood and
urine.1,7,12–15 Furthermore, several studies reported that
serum and urinary Ngal levels are elevated proportionally to
the extent of renal damage in chronic kidney disease,16,17 but
the source and the time course of urinary Ngal concentrations
are largely unknown. In this study, we investigated urinary
Ngal levels in four types of renal damage caused by distinct
mechanism: nephrotic syndrome caused by glomerular
disorders, diabetic nephropathy, obstructive nephropathy,
and interstitial nephritis. We also examined whether measure-
ment of urinary Ngal is useful for the monitoring of renal
damage in mice or humans during the treatment course.
RESULTS
Urinary Ngal excretion is proportional to albumin excretion
in mouse models of diabetic nephropathy
As a model of diabetic nephropathy, we first examined
urinary Ngal concentrations in A-ZIP/F-1 transgenic mice,
which are characterized with lipoatrophic diabetes, fatty liver,
hyperlipidemia, severe insulin resistance, and massive
proteinuria.18–20 Urinary Ngal excretion in A-ZIP/F-1 mice
at 10 months of age was much larger than that in control
FVB/N mice (Figure 1). By Western blot, we observed 30 and
25 kDa bands with Ngal immunoreactivity, and the larger
band was found only in the urine from A-ZIP/F-1 mice and
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not in the urine or tissues from normal, diabetic, or
obstructed kidneys of mice with C57BL/6 background (see
below). The larger protein may have heavier glycosylation
than the smaller protein.21 When the amounts of two
proteins were added, mice with larger urinary Ngal levels
tended to have larger urinary albumin levels.
Next, we studied streptozotocin (STZ)-induced diabetes,
which manifests with insulin deficiency and microalbumi-
nuria. In STZ mice, urinary albumin excretion increased
gradually and, after 8 weeks, reached 7.8-fold of the level
before STZ injection (Figure 2). On the other hand, urinary
Ngal levels were elevated by 77-fold at 8 weeks. The extent of
Ngal and albumin excretion was highly variable among
different mice, but urinary albumin levels and log transfor-
mation of Ngal levels showed a close linear correlation
throughout the course of 12-week observation period.
Elevation of urinary Ngal excretion in STZ mice is not caused
by renal synthesis but by reabsorption defect, and treatment
with angiotensin receptor blocker reduces urinary Ngal levels
To examine whether local expression of Ngal is increased in
STZ mouse kidneys, we studied expression levels of Ngal
protein in the whole kidney preparation of STZ and non-STZ
control mice and found no significant difference at 8 weeks
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Figure 1 | Urinary Ngal and albumin excretion in two models of diabetic nephropathy. (a–c) A-ZIP/F-1 diabetic mice at 10 months of
age and (d, e) diabetic mice at 8 weeks after streptozotocin (STZ) injection. (a, d) Western blot of urine (25 ml each) in individual mice and
(b, c, e) urinary levels of Ngal and albumin (Alb) normalized by creatinine (Cr) are shown. (b) A-ZIP/F-1 mice, including no. 1, excreted
much larger volumes of urine than control FVB/N mice. In three control FVB/N mice, mean urinary Ngal/Cr ratio (±s.e.) was 42±24 ng per
mgCr. uNgal, urinary Ngal; rNgal, recombinant Ngal.
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after STZ treatment (Figure 3). We did not find significant
alteration of Ngal protein expression in the livers, either.
Of note, serum Ngal levels in STZ mice were significantly
lower than those in non-STZ mice (23±5 versus 111±22 ng/
ml, n¼ 3–4, Po0.01). We measured Ngal mRNA expression
levels in the kidneys and livers of STZ mice, but they
were increased only marginally compared to control mice.
As a positive control, Ngal mRNA expression was increased
by 100-fold in obstructed kidneys after 1 day of ureter
ligation (Po0.001). These findings suggested that dramatic
(nearly 80-fold) increase of urinary Ngal excretion in STZ
mice cannot be explained by augmentation of Ngal
protein synthesis in the kidney, and led us to investigate
tubular reabsorption of Ngal. Injection of histidine-tagged or
Alexa Fluor 546-labeled Ngal (21 kDa in size) in the
peritoneum of non-STZ mice resulted in glomerular filtra-
tion and efficient reabsorption of Ngal at the proximal
tubules from the apical side, thus no exogenous Ngal was
detected in the urine (Figure 4). In STZ mice, on the other
hand, substantial amount of exogenous Ngal was excreted in
the urine and reabsorption of labeled Ngal was reduced by
47% (Po0.01).
As treatment of diabetic nephropathy with angiotensin
receptor blocker (ARB) reduces proteinuria and ameliorates
renal injury,22 we gave the ARB candesartan to STZ mice
through drinking water at 10 mg/kg/day (Figure 5). After 1
week, urinary albumin levels were decreased by 14%
(Po0.05) and urinary Ngal levels were decreased by 77%
(Po0.05). Serum Ngal levels were not altered by candesartan
(20±6 ng/ml). The dose of candesartan used was a
subdepressor dose, and did not significantly affect body
weights, blood glucose, urea nitrogen and creatinine levels
(Table 1). Through these findings, we conclude that increased
urinary Ngal excretion in STZ mice was caused mainly by
reabsorption defect and treatment with candesartan partially
normalized urinary Ngal levels.
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Figure 2 | Time course and correlation of urinary Ngal and
albumin excretion in streptozotocin (STZ)-induced diabetic
mice. (a) Urinary Ngal (uNgal) and albumin (uAlb) levels
normalized by urinary creatinine (uCr) were examined before and
at 4, 8, and 12 weeks after STZ injection (mean±s.e.). #, Po0.05
versus pre-STZ. Elevation of urinary Ngal levels was significant at
4, 8, and 12 weeks if analyzed after log transformation. (b)
Correlation between uNgal/uCr and uAlb/uCr; r¼ 0.86, Po0.001,
n¼ 19.
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Figure 3 | Ngal protein and mRNA expression in the serum,
kidney, and liver of STZ mice. (a) Western blot of serum, whole
kidney, and liver at 8 weeks after induction of diabetes. Mice
without STZ injection served as control (non-STZ). Equal amounts
of serum (15ml) and protein (30 mg) of whole kidney and liver
were separated by electrophoresis; rNgal, recombinant Ngal. (b)
Ngal mRNA expression levels were measured using real-time PCR
and normalized by GAPDH expression (n¼ 4). The mean Ngal/
GAPDH level in non-STZ whole kidney was arbitrarily defined as
1.0. The whole kidneys at 1 day after unilateral ureteral
obstruction (UUO) were also examined as a positive control. NS,
not significant.
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Urinary Ngal levels are highly elevated in human cases of
nephrotic syndrome and are decreased in response to
treatment
As cases of glomerular disorders with nephrotic syndrome,
we investigated the clinical courses and changes in serum and
urinary Ngal levels in human subjects. Case 1 was a 68-year-
old woman with biopsy-proven minimal change disease. She
had nephrotic range proteinuria (14 g/day) and gained body
weight by 15 kg (from 62 to 77 kg) within 3 weeks. She was
treated with i.v. steroid pulse (methyl prednisolone 1 g 3
days), followed with oral prednisolone (beginning with
35 mg/day), and with three courses of hemodialysis on days
8, 9, and 12 after admission (Figure 6). Her proteinuria,
edema, and azotemia resolved gradually. Concomitantly,
urinary and serum Ngal levels decreased during the
treatment, but reduction was much faster for urinary Ngal
levels. There was a temporal elevation of urinary Ngal levels
on day 21, which might reflect the reappearance of oligouria
or proteinuria.
Case 2 was a 26-year-old woman, who was diagnosed
to have membranous-type lupus nephritis (ISN/RPS
class V). She was treated with two courses of i.v. steroid
pulse, followed with oral prednisolone (Figure 6). Her
urinary levels of protein and Ngal were decreased sharply
within 17 days.
Case 3 was a 55-year-old woman with clinically diagnosed
lupus nephritis (no biopsy). She had been treated with two
courses of i.v. steroid pulse (1 g 3 days) and oral
prednisolone had been tapered from 50 to 35 mg/day, before
changing the hospitals to ours. She was given i.v. cyclo-
phosphamide pulse (0.4 g, once, 6 days after admission) and
the immunosuppressant mizoribine (Asahi Kasei Pharma,
Osaka, Japan; 100 mg/day). Urinary excretion of protein and
Ngal decreased slowly (Supplementary Figure S1). Serum
creatinine levels were constant throughout the course
(0.4–0.5 mg/100 ml).
Case 4 was a 69-year-old man, who suffered from rapidly
progressing, crescentic glomerulonephritis accompanied
with moderate tubulointerstitial damage. His serum con-
tained myeloperoxidase-type antineutrophil cytoplasmic
antibody (MPO-ANCA, 138 EU). The maximum serum
creatinine level was 5.6 mg/100 ml, and the proteinuria and
azotemia responded slowly to treatment containing oral
and i.v. steroid and i.v. cyclophosphamide (Supplementary
Figure S1). Macrohematuria was observed, peaking at 5 days
after cyclophosphamide administration. After 10 months,
he showed signs of recurrence which were worsening in
proteinuria, hematuria, azotemia, and MPO-ANCA titer
(from o10 to 37 EU). We observed reelevation of urinary
Ngal levels during acute worsening of nephritis. Cyclosporine
A (75 mg/day before breakfast) was added at 13 months,
which appeared to support reduction of above mentioned
signs.
To understand renal localization of Ngal protein in
nephrotic patients, we carried out immunofluorescence study
of renal biopsy samples and found close colocalization of
signals of Ngal and albumin at the apical side of tubules. The
results for case 1 are shown in Figure 7. These findings are
consistent with those in animal experiments shown above
(Figure 4), indicating highly active reabsorption of Ngal from
glomerular filtrate.
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Figure 4 | Urinary excretion and tubular reabsorption of
exogenously administered Ngal in STZ mice. (a) Western blot
of urinary Ngal detected either with anti-Ngal or with anti-His-tag
antibody at 8 weeks after induction of diabetes. Urine samples
were collected for 12 h after His-tagged Ngal injection (i.p.) and
25ml aliquots of them were separated by electrophoresis. Of note,
STZ mice excreted much more diluted urine compared to non-STZ
control mice. 1, endogenous Ngal (25 kDa, glycosylated); 2, His-
tagged Ngal (21 kDa, unglycosylated). (b) Alexa Fluor 546-labeled
Ngal was injected into STZ mice and kidneys were examined
30 min later. Arrows indicate Ngal protein distribution (in orange),
which was homogeneous in non-STZ but was irregular and sparse
in STZ mice. Top right panel shows selected area (in green) of
positive fluorescence by computer software. G, glomeruli.
Magnification,  20. (c) Quantitation of exogenous Ngal uptake in
kidneys of STZ and non-STZ mice (n¼ 4).
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In mice with obstructive nephropathy, Ngal protein is
specifically located in the distal nephrons in the obstructed
side by local synthesis, whereas it is confined to the proximal
tubules in the contralateral side of the kidneys by
reabsorption
As a model of post-renal kidney injury, we investigated mice
with unilateral ureteral obstruction (UUO), in which distal
nephrons are primarily affected, and studied the changes of
Ngal protein levels in the obstructed and nonobstructed sides
of the kidneys, serum, and urine (Figures 7 and 8). We also
determined the renal distribution of Ngal by immunohis-
tochemistry along with nephron segment markers: aquaporin
(AQP) 1 for proximal tubules, Tamm-Horsfall protein (THP)
for thick ascending limbs of Henle, and AQP 2 for collecting
ducts (Figure 7; Figures S2–S4). In the UUO kidneys, after 1
day of ureter ligation, Ngal protein was expressed exclusively
in thick ascending limbs of Henle, which was also expressing
THP and was prominently dilated, suggesting that Ngal was
synthesized in damaged epithelia. By striking contrast, in the
contralateral kidneys, Ngal protein was confined to the apical
side of aquaporin 1þ proximal tubules. Ngal protein levels in
the obstructed kidneys and in the urine from the dilated
pelvis were continuously elevated for 2 weeks, whereas those
in the nonobstructed kidneys and in the serum peaked at day
1 and decreased gradually. A smaller (17 kDa) fragment
detected in the kidneys (but not in the urine and serum)
using polyclonal anti-Ngal antibody may have been generated
by lysosomal proteolysis of Ngal in the tubules.2 Ngal mRNA
expression was elevated by 100-fold in the obstructed kidneys
(Figure 3), but it was only elevated by threefold in the
contralateral kidneys at day 1 (data not shown). These
findings indicate that Ngal was synthesized de novo in distal
nephrons of obstructed kidneys, although it was highly but
transiently accumulated in the serum, filtrated and reab-
sorbed in the contralateral kidneys.
In a case with interstitial nephritis, urinary Ngal levels
decreased more rapidly than classic markers of tubular injury
Next, we investigated whether urinary Ngal is useful for
evaluation of renal disorder with low-level proteinuria. Case
5 was a 25-year-old man, who was admitted to our hospital,
presenting with general malaise, proteinuria (0.4 g/day), renal
glucosuria and mild azotemia. He had taken an over-the-
counter cold medicine 6 weeks earlier, and was positive in
lymphocyte stimulation test for the drug. Renal biopsy
revealed subacute interstitial nephritis with minor glomerular
lesions. His signs and symptoms resolved by oral and i.v.
prednisolone treatment. Table 2 and Figure S5 summarize the
clinical course and changes in urinary biomarkers. The
time to 50% reduction of urinary markers was in the
order of Ngal p (total) proteinoa1- and b2-micro-
globulins (classic markers of tubular proteinuria)
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Figure 5 | Reduction of urinary Ngal and albumin excretion by candesartan in STZ mice. (a) Urinary Ngal (uNgal) and (b) albumin (uAlb)
levels at 4 and 8 weeks after STZ injection and after one more week with candesartan (10 mg/kg/day, orally) or vehicle treatment (n¼ 4).
Table 1 | Blood glucose, urea nitrogen, creatinine levels, body weight, and blood pressure in STZ diabetic mice before and after
candesartan treatment
Vehicle Candesartan
Before After Before After
Blood glucose (mg/100 ml) 598±2 593±6 600±3 591±5
HbA1c (%) 11.7±0.5 ND 12.5±0.2 ND
Blood urea nitrogen (mg/100 ml) ND 50±2 ND 54±1
Serum creatinine (mg/100 ml) ND 0.13±0.01 ND 0.11±0.01
Body weight (g) 23.8±0.9 23.5±0.7 22.4±0.5 22.8±0.5
Systolic blood pressure (mm Hg) 104±2 105±0.9 103±1 100±1
Diastolic blood pressure (mm Hg) 55±2 56±1 50±1 49±2
Treatment with candesartan did not significantly alter these parameters. Blood urea nitrogen and serum creatinine levels in non-STZ control mice were 23±3 and
0.09±0.02 mg/100 ml, respectively. Blood was drawn when mice were fed ad libitum. ND, not determined.
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oN-acetyl-b-D-glucosaminidase. The fold-change during
treatment was also largest in urinary Ngal, suggesting that
urinary Ngal may be useful in monitoring the activity of
nonglomerular renal disorders.
DISCUSSION
In the present study, we investigated urinary Ngal concentra-
tions in patients with nephrotic syndrome (caused by acute
and severe glomerular disorders) and interstitial nephritis
and in mouse models of diabetic or obstructive nephropathy
and found that the levels were unequivocally elevated (over
10-fold of control). In diabetic mice induced by STZ (as a
model of slowly progressive chronic kidney disease), urinary
Ngal appeared to derive mostly from impaired reabsorption
in proximal tubules. In obstructed kidneys (as a model of
post-renal AKI), Ngal was highly expressed in distal nephrons
and accumulated in the urine collected from the pelvis.
Therefore, STZ-diabetic and obstructed kidneys are the two
extreme examples in which the primary source of urinary
Ngal is glomerular filtrate and renal synthesis, respectively. In
human renal disorders, urinary Ngal should be a mixture of
these two major components. These findings indicate that in
a variety of kidney diseases, urinary Ngal is a biomarker that
can reflect damage in glomeruli, proximal tubules and distal
nephrons.
Cross-sectional studies published so far have elucidated
that urinary Ngal levels show certain correlation with urinary
protein levels.16,23 To our knowledge, this is the first human
report to show very rapid and simultaneous reduction of
urinary Ngal and protein concentrations by medical inter-
vention. Surprisingly, the time course of urinary Ngal levels
was associated to that of urinary protein levels not only in
diabetic nephropathy and minimal change disease but also in
crescentic glomerulonephritis and interstitial nephritis. In the
latter disorders, treatment with steroid and immunosuppres-
sant may have ameliorated Ngal reabsorption impairment
and epithelial Ngal synthesis at the same time. The present
findings suggest that urinary Ngal may be useful in the
monitoring of disease activity and treatment efficacy. Of
note, we cannot overgeneralize the findings in this study to
all renal disorders, especially because we did not examine
patients with severe, acute tubular necrosis, for instance,
caused by renal ischemia or nephrotoxins (in which Ngal is
abundantly synthesized by renal epithelia).2
In diabetic nephropathy, albumin excretion is increased by
leakage from glomerular filtration barrier.24 On the other
hand, a number of reports elucidated the involvement of
tubular dysfunction as a cause of albuminuria.24–27 The size of
Ngal protein (25 kDa) is smaller than albumin and, in normal
conditions, Ngal is rapidly filtered by glomeruli and
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Figure 6 | Clinical course of 2 cases with nephrotic syndrome. (a) minimal change disease (case 1, MCD) and (b) lupus nephritis (case 2,
LN). mPSL, methyl prednisolone; PSL, prednisolone; uProt, urinary protein excretion; sNgal, serum Ngal; uNgal, urinary Ngal; BUN, blood urea
nitrogen; sCr, serum creatinine; uNgal/uCr, urinary Ngal normalized by urinary creatinine; Ab, antibody.
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reabsorbed very efficiently by proximal tubules, leaving only
0.1–0.2% in the urine.2 By analyzing renal handling of
exogenously injected Ngal, the present study emphasized the
existence of tubular reabsorption impairment in diabetic
nephropathy.28 In reverse, cellular stress in the proximal
tubules may cause deterioration in diabetic nephropathy, as
it was reported that transgenic overexpression of catalase in the
proximal tubules of mice attenuated development of hyper-
tension and albuminuria associating diabetic nephropathy.29
Treatment of STZ-diabetic mice with ARB signi-
ficantly reduced urinary excretion of both Ngal and albumin.
Two major scenarios can be proposed. First, ARB directly
improved reabsorption efficiency in the proximal tubules,
which may be mediated by increased peritubular capillary
blood flow30 and by amelioration of oxidative stress.31
Second, ARB reduced intraglomerular hypertension and
hyperfiltration,32 reduced albumin leakage from glomeruli,
and the total amount of the ligands for the common
scavenger receptor megalin was decreased in the tubular
lumen. This may increase the ratio of Ngal and albumin
endocytosed at proximal tubules.
Here we used high-dose STZ to induce a model of diabetic
nephropathy. Direct toxicity of STZ to proximal tubules may
have exaggerated the elevation of urinary Ngal levels in these
mice (which is 77-fold of control mice).33 Hyperfiltration is
reported in rodents given STZ.32 In a previous report,
threefold elevation in creatinine clearance was observed in
C57BL/6 mice after treatment with STZ, but serum creatinine
levels were not significantly decreased, likely due to
concomitant osmotic diuresis and dehydration.34 In the
present study, hyperfiltration may have similarly occurred in
STZ-diabetic mice. Growth arrest and leanness of STZ-
diabetic mice may be partly related to selective reduction of
serum Ngal levels (but not serum creatinine and BUN levels)
in the present study, as obesity has been shown to be
associated with elevated circulating Ngal levels.35
We also observed abundant urinary Ngal excretion in 4
patients with nephrotic syndrome. The mechanism may involve
direct competition between Ngal and albumin at the surface of
megalin molecule for receptor-mediated endocytosis26,36 and
also general malfunctioning of proximal tubules because of
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Figure 7 | Localization of Ngal protein expression in human
and mouse kidneys. Immunofluorescence of (a, green) albumin
and (b, red) Ngal in a patient with minimal change disease (MCD,
magnification  40). Arrows, colocalization of signals; asterisks,
tubular lumen. Immunohistochemistry of (c, d) Ngal, (e) aquaporin
1 (AQP1), and (f) Tamm-Horsfall protein (THP) in the mouse kidney
treated with (d, f) unilateral ureteral obstruction (UUO) and in the
(c, e) contralateral kidney (UUN) at 1 day after operation (original
magnification,  20). Serial sections were analyzed.
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Figure 8 | Ngal protein levels in UUO, UUN, serum, and urine
in mice with kidney obstruction. (a) Western blot analysis of
Ngal protein. ND, not determined. (b) The mean Ngal
concentrations in UUO, UUN, serum, and urine (collected from
dilated pelvis of the UUO side using a needle and syringe).
Elevation of Ngal concentrations were statistically significant at
day 1 in UUO or UUN kidneys and serum, and at day 3 in urine
(Po0.01 by unpaired t-test, n¼ 3) compared to day 0 (no
operation).
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protein overload. Furthermore, a fraction of urinary Ngal may
originate from renal synthesis in addition to reabsorption
defect, but Ngal gene expression in human samples was not
investigated in this study. The time required for urinary Ngal
reduction was variable among cases: ranging from 2 weeks
(cases 1 and 2) to more than a month (cases 3 and 4).
In a case with interstitial nephritis, urinary Ngal showed
the largest fold increase and the quickest response to steroid
treatment in comparison to other urinary biomarkers: total
protein, a1- and b2-microglobulins and N-acetyl-b-D-
glucosaminidase. These findings suggest that urinary Ngal
might be particularly useful in the evaluation of kidney
recovery in patients with low-grade proteinuria.
To summarize, urinary Ngal is a rapid biomarker of
kidney injury and recovery showing a large fold-increase or
decrease during clinical course of various renal disorders.
Proteinuria seems to be one of important factors affecting
Ngal’uria.
MATERIALS AND METHODS
Animal experiments
All animal experiments were conducted in accordance with our
institutional guidelines for animal research. Male A-ZIP/F-1
heterozygous transgenic mice and control FVB/N littermates were
used at 10 months of age, when A-ZIP/F-1 mice exhibit diabetic
nephropathy with massive proteinuria.18–20 Other animal experi-
ments were carried out with male C57BL/6J mice (Japan Clea,
Tokyo, Japan) starting at 8 weeks of age, when they weighted
21–23 g. Diabetes was induced by intraperitoneal injection of STZ
(180 mg/kg of body weight; Sigma, St. Louis, MO, USA) in citrate
buffer (pH 4.6) and control mice received only citrate buffer. Blood
pressure was measured by the indirect tail-cuff method with MK-
2000ST (Muromachi Kikai, Tokyo, Japan). Urine samples were
collected with metabolic cages. Urinary albumin was measured with
murine albumin ELISA (Exocell, Philadelphia, PA, USA). Serum and
urinary creatinine levels were assayed by the enzymatic method
(SRL, Tokyo, Japan). This method gives reliable measurement when
compared to high-performance liquid chromatography method,
even in low concentration materials, and performs much better than
Jaffe’s colorimetric method.37 Blood glucose and HbA1c levels were
determined in tail vein blood at ad libitum-fed conditions using
Glutest Ace (Sanwa Kagaku, Nagoya, Japan) and DCA2000þ
Analyzer (Bayer Medical, Tokyo, Japan), respectively. Mice were
killed under pentobarbital anesthesia before organ collection.
Prodrug of candesartan, candesartan cilexetil (TCV-116; Takeda
Chemical Industries, Osaka, Japan), was initially dissolved at 10 mg/
ml in a solution containing 16% polyethylene glycol no. 300 (vol/
vol; Nacalai, Kyoto, Japan), 16% ethanol (Nacalai), and 0.7 M
Na2CO3, and further diluted in drinking water to be given at a final
dose of 10 mg/kg/day. This treatment method38 gave less blood
pressure lowering effects compared to gavage administration as
previously described.39 For UUO, mice were anesthetized with
pentobarbital, the left kidney was exposed by midline incision, and
the left ureter was ligated with 4–0 silk at two points.40 Mice were
killed 1–14 days after the operation.
Recombinant Ngal injection and detection
To investigate renal reabsorption of Ngal, 200mg of 6 histidine-
tagged (at the C terminus) or 60 mg of Alexa Fluor 546 (Molecular
Probes, Eugene, OR, USA)-labeled recombinant mouse Ngal
(expressed in BL21 strain of Escherichia coli)2 was injected into
the peritoneum of mice. Urine samples were collected for 12 h after
His-tagged Ngal injection. Urinary excretion of administered
His-tagged Ngal was evaluated by Western blot analysis described
below with anti-His antibody (MBL, Nagoya, Japan) or with goat
polyclonal anti-mouse Ngal antibody (R&D Systems, Minneapolis,
MN, USA). Kidneys were harvested 30 min after Alexa Fluor
546-labeled Ngal injection, snap frozen, sliced at 10 mm thickness
and examined by a fluorescence microscope (IX81-PAFM; Olympus,
Tokyo, Japan). The signal-positive areas were measured using
MetaMorph 7.5 software (Molecular Devices, Downingtown, PA, USA).
Patients and measurement of human Ngal
Patients who admitted to Kyoto University Hospital for the
diagnosis and treatment of renal disorders were enrolled under
informed consent. This study was approved by the ethical
committee on human research of Kyoto University Graduate School
of Medicine. Ngal concentrations in the human serum and urine
were determined by sandwich ELISA (AntibodyShop, Gentofte,
Denmark) usually after 1000- and 250-fold dilution, respectively.
Western blot analysis
Urine, serum, and proteins extracted from organs were separated by
SDS–polyacrylamide gel electrophoresis, transferred onto polyviny-
lidene difluoride membranes, incubated with primary antibody and
detected with peroxidase-conjugated secondary antibody and
Table 2 | Changes of urinary biomarker levels in case 5 (interstitial nephritis)
Days after admission 9 37 Fold differencea Normal value
uNgal/uCr (mg/gCr) 256.6 25.4 10.1 o10mg/lb
uProt/uCr (g/gCr) 0.381 0.052 7.3 o0.15 g/day
ub2MG/uCr (mg/gCr) 18.2 2.8 6.5 o0.3 mg/l
ua1MG/uCr (mg/gCr) 46.4 17.2 2.7 o15 mg/l
sNgal (mg/l) 224 90 2.5 o106mg/lb
uNAG/uCr (U/gCr) 21.1 8.7 2.4 o7 U/l
BUN (mg/100 ml) 15 11 1.4 o22 mg/100 ml
sCr (mg/100 ml) 1.2 1.0 1.2 o1.1 mg/100 mlc
MG, microglobulin; NAG, N-acetyl-b-D-glucosaminidase; Prot, protein; u and sNgal, urinary and serum Ngal; uCr, urinary creatinine.
aFold difference between days 9 and 37.
bValue suggested by ELISA kit supplier.
co1.1 for man and o0.8 for woman.
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chemiluminescence. Serum was passed through 100-kDa cutoff
membrane (Microcon YM-100; Millipore, Bedford, MA, USA) to
remove immunoglobulins before analysis.2 The amount of Ngal
protein was measured by densitometry. Known amounts of
recombinant mouse Ngal protein were used as standards.2
Real-time reverse transcription PCR
Total RNA was extracted from mouse kidneys and livers with TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and cDNA in each sample
was synthesized by High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). The mRNA levels of
Ngal were determined using Premix Ex Taq (Takara Bio, Otsu,
Japan) and ABI Prism 7300 Sequence Detector with the following
primers and probe: Ngal forward, 50-ggcagctttacgatgtacagca-30; Ngal
reverse, 50-tctgatccagtagcgacagcc-30; Ngal probe, 50-FAM-catcctggt-
cagggaccaggaccag-TAMRA-30. Expression levels of Ngal were
normalized by glyceraldehyde-3-phosphate dehydrogenase (internal
control) levels, whose primer–probe set was purchased from Applied
Biosystems.41 Standard curve was made by serial dilution of cDNA
from UUO kidneys.
Immunofluorescence of Ngal and albumin
Snap-frozen human biopsy samples were sliced at 3 mm thickness,
fixed with acetone, and incubated with a solution containing both
fluorescein isothiocyanate-labeled rabbit anti-human albumin anti-
body (Dako, Glostrup, Denmark) and goat polyclonal anti-human
Ngal antibody (R&D Systems), followed by incubation with
TexasRed-labeled anti-goat IgG (Jackson Immunoresearch, West
Grove, PA, USA). The spillover of each signal was negligible.
Immunohistochemistry of Ngal and nephron markers
Mouse kidneys were fixed in 4% paraformaldehyde at 4 1C for 12 h
and embedded in paraffin. Renal sections of 4 mm were deparaffined,
hydrated, and incubated with 0.3% hydrogen peroxide. Antigen
retrieval was performed by 0.05 mol/l citrate buffer (pH 6.0) for
10 min in a water bath heated at 100 1C (for Ngal, AQP1 and AQP2),
or in a microwave oven (for THP). After cooling, the sections were
incubated with 10% normal donkey or goat serum, followed by goat
anti-mouse Ngal (1:300; R&D Systems), rabbit anti-AQP1 and
AQP2 (1:200; Chemicon International, Temecula, CA, USA), or
rabbit anti-THP antibodies (1:200; Biomedical Technologies,
Stoughton, MA, USA). Primary antibodies were visualized with
horseradish peroxidase-conjugated secondary antibodies and 3,3-
diaminobenzidine tetrahydrochloride. Nuclei were counterstained
with hematoxylin.
Statistical analysis
Results are expressed as mean±s.e. Student’s t-test was carried out
to compare two groups. Statistical significance was defined as
Po0.05.
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